2. Epogen/Aranesp - Top 10 Warnings and Recalls

Drug: Epogen/Aranesp

2006 sales: 4.1 B/$2.5 B

Manufacturer: Amgen

Safety concern: “black box;” heart and vascular problems at higher doses

Related Articles:
> Analyst: Anemia drug warnings 'not bad'. Report
> Amgen income hammered as anemia drug use drops. Report
> Amgen, J&J win a round in anemia controversy. Report
> Amgen discusses the future with analysts. Report
> New rules limit use of anemia drugs. Report
> Amgen stock slips as anemia drug concerns rise. Report
> New study points to danger of anemia drug. Report

2. Epogen/Aranesp - Top 10 Warnings and Recalls
Read more on

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.